Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | DGKA | P23743 | 2/20 | 0.49 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.46 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14239784 | 0.97 | DNM1 (0.63) | DNM1EPHX2MGLLALDH1A1MAPT | |
| SCHEMBL18350892 | 0.95 | DNM1 (0.58) | DNM1EPHX2MGLLALDH1A1MAPT | |
| SCHEMBL18350944 | 0.94 | DNM1 (0.59) | DNM1MGLLALDH1A1MAPTTHRB | |
| SCHEMBL12179617 | 0.94 | DNM1 (0.65) | DNM1EPHX2MGLLALDH1A1MAPT | |
| SCHEMBL17877550 | 0.93 | DNM1 (0.58) | DNM1MGLLALDH1A1MAPTTHRB | |
| SCHEMBL15027026 | 0.93 | DNM1 (0.57) | DNM1EPHX2MGLLALDH1A1MAPT | |
| SCHEMBL12247274 | 0.92 | DNM1 (0.57) | DNM1EPHX2MGLLALDH1A1MAPT | |
| SCHEMBL17613217 | 0.92 | DNM1 (0.57) | DNM1EPHX2MGLLALDH1A1MAPT | |
| SCHEMBL17586392 | 0.92 | DNM1 (0.74) | DNM1MAPTDGKA | |
| SCHEMBL21026912 | 0.92 | DNM1 (0.59) | DNM1EPHX2MGLLALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2858974-B9 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORP (JP) | 2022-07-20 | — | — | EP | disclosed |
| EP-3489220-B9 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORP (JP) | 2021-11-10 | — | — | EP | disclosed |
| EP-3489220-B1 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORP (JP) | 2021-08-18 | — | — | EP | disclosed |
| EP-3127915-B1 | RBP-DERIVED TARGETING MOLECULE AND UTILIZATION THEREOF | NITTO DENKO CORP (JP) | 2020-08-26 | — | — | EP | disclosed |
| US-20200085957-A1 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORPORATION (JP) | 2020-03-19 | — | — | US | disclosed |
| US-10441659-B2 | Lipids for therapeutic agent delivery formulations | NITTO DENKO CORPORATION (JP) | 2019-10-15 | — | — | US | disclosed |
| US-20190275158-A1 | SKIN FIBROSIS TREATMENT AGENT | NITTO DENKO CORP (JP) | 2019-09-12 | — | — | US | disclosed |
| EP-3536343-A1 | SKIN FIBROSIS TREATMENT AGENT | Nitto Denko Corporation (JP) | 2019-09-11 | — | — | EP | disclosed |
| EP-3489220-A1 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | Nitto Denko Corporation (JP) | 2019-05-29 | — | — | EP | disclosed |
| US-9976142-B2 | Targeting molecule and a use thereof | NITTO DENKO CORPORATION (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9976142-B2 | Targeting molecule and a use thereof | NITTO DENKO CORPORATION (JP) | 2018-05-22 | — | — | US | disclosed |
| EP-3127915-A1 | TARGETING MOLECULE AND UTILIZATION THEREOF | Nitto Denko Corporation (JP) | 2017-02-08 | — | — | EP | disclosed |
| US-20170022500-A1 | A TARGETING MOLECULE AND A USE THEREOF | NITTO DENKO CORPORATION (JP) | 2017-01-26 | — | — | US | disclosed |
| US-20170022500-A1 | A TARGETING MOLECULE AND A USE THEREOF | NITTO DENKO CORPORATION (JP) | 2017-01-26 | — | — | US | disclosed |
| US-9308267-B2 | Lipids for therapeutic agent delivery formulations | NITTO DENKO CORPORATION (JP) | 2016-04-12 | — | — | US | disclosed |
| US-9308267-B2 | Lipids for therapeutic agent delivery formulations | NITTO DENKO CORPORATION (JP) | 2016-04-12 | — | — | US | disclosed |
| US-20160074514-A1 | Lipids for Therapeutic Agent Delivery Formulations | NITTO DENKO CORPORATION (JP) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022500-A1 | A TARGETING MOLECULE AND A USE THEREOF | STRA6, RBP1, FABP1 | DNM1 2752/4885EPHX2 4504/4885MGLL 3801/4885 |
| US-20160074514-A1 | Lipids for Therapeutic Agent Delivery Formulations | LIPA, SGMS2, SGMS1 | DNM1 235/4885EPHX2 1794/4885MGLL 84/4885 |
| US-20200085957-A1 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | LIPA, SGMS2, SGMS1 | DNM1 235/4885EPHX2 1794/4885MGLL 84/4885 |
| US-10441659-B2 | Lipids for therapeutic agent delivery formulations | LIPA, SGMS2, SGMS1 | DNM1 235/4885EPHX2 1794/4885MGLL 84/4885 |
| US-20190275158-A1 | SKIN FIBROSIS TREATMENT AGENT | COL1A1, COLGALT1, COL14A1 | DNM1 4615/4885EPHX2 445/4885MGLL 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.